The progressive airflow limitation has been shown by the classical work of Fletcher and Peto in the seventies and became the basis of the introduction of spirometry into the diagnosis of COPD [5, 6] . A ratio of FEV1/FVC below 0.7 is now required to classify a patient with symptoms such as dyspnea, cough and sputum as COPD [1, 4] .
Although the "preventable" element is stated in the definition, the disease is usually diagnosed very late and this has significant consequences on the natural history of the disease [4]. It is well known that the susceptible individual in order to develop the disease needs to be exposed to risk factors for long time, more than a decade [1, 4, [6] [7] .
During this prolong pre-clinical period of the natural history of the disease significant changes occurs in the lungs on molecular and cellular level [8] [9] [10] [11] [12] . The small airways, in the periphery of the lungs, are usually the site where the initiation of those alterations could be detected [13] . Thereafter, those pathological changes may proceed towards the larger airways developing the phenotype of chronic bronchitis or towards the alveoli, causing emphysema or more commonly in both directions, developing the frequent phenotype of both entities (chronic bronchitis and emphysema) in the same patient, the so called COPD patient [14, 15] .
During this phase of the disease the above morphological changes produce symptoms such as breathlessness, cough and sputum. Usually, these symptoms appear well before the functional changes could be detected by spirometry (FEV1/FVC <0.7). Recent studies had confirmed these observations showing that current or ex-smokers with preserved pulmonary function have symptoms, exacerbations and activity limitation equivalent that seen in COPD patients [14] .
Thus, this early pre-clinical phase, according to the definition of COPD, is extremely important because if the disease is detected during this stage and managed appropriately, the natural history of the disease may be altered immensely. Previously, this subclinical stage was defined as STAGE 0 by the first guideline documents by GOLD but it disappeared from the subsequent ones [1, 15] .
Since, during this long pre-clinical phase of the natural history of the disease the most significant molecular, cellular and histological changes occur, it would be of great scientific value to focus our research on it [16] .
Therefor, I do recommend the re -establishment of Stage O of COPD, defining the patients with exposure to risk factors, having the symptoms of the disease (dyspnea, cough and sputum), but with preserved lung function. I do believe, that if we have STAGE 0 back in the guidelines, we will enhance the research on the pathophysiology of its early phase, in other wards, at the beginning of COPD [16, 17] . In addition, STAGE 0 will increase the awareness of the disease and if the appropriate measures will be taken ,this would modify the natural history of COPD, reducing immensely the burden the disease..
